Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Aeluma reported Q1 fiscal 2027 financial results with revenue of $0.6M and a net loss of $3.8M. The company highlighted a new purchase agreement with Aixtron for MOCVD manufacturing expansion and ongoing negotiations for $30M in CHIPS Act funding.
Term
Q1 2027
“The current U.S. AI infrastructure buildout continues to progress and is expected to reach an aggregate investment of $10.3 trillion in 2032. The opportunities for photonics are vast, spanning scale-up and scale-out AI architectures in data centers.”
Jonathan Klamkin, Ph.D., Founder and CEO
“As we progress through fiscal 2027, we remain focused on technology and product development for AI Datacom opportunities. Aeluma’s high-speed photodetectors and quantum dot lasers continue to attract customer attention.”
Sutro Biopharma reported third quarter 2026 financial results, highlighting a cash position of $142.2 million which is expected to fund operations into the first half of 2028. The company advanced its clinical pipeline with the first patient dosed in the STRO-006 Phase 1 study and reported progress on its STRO-004 and STRO-227 ADC programs.
Term
3 months
“Over the past year, we have delivered on our commitment to advance our next-generation ADCs with two programs, STRO-004 and STRO-006, entering the clinic in less than a year, and our dual-payload ADC, STRO-227, expected to follow in early 2027.”
Jane Chung, Chief Executive Officer of Sutro
“Early data from STRO-004 give us confidence in its potential to deliver meaningful clinical benefit with our proprietary ADC platform. In addition, our collaboration partner Astellas has initiated patient dosing with a second dual-payload immunostimulatory ADC, further highlighting our strong execution and ability to deliver differentiated, novel dual-payload ADCs.”
Live Oak Bancshares, Inc. closed an underwritten public offering of 4,000,000 depositary shares, each representing a 1/40th interest in its 8.750% Fixed Rate Series B Non-Cumulative Perpetual Preferred Stock. The offering raised approximately $96.25 million in net proceeds after underwriting discounts and expenses, with the shares carrying a liquidation preference of $25 per depositary share.
Stark Novus Financial Inc. held its 2026 Annual Meeting of Stockholders on November 9, 2026. Shareholders elected Paul Burkett and Alexandre Zyngier as Class II directors for three-year terms and ratified BDO USA, P.C. as the company's independent accounting firm for the 2026 fiscal year.
PIMCO Capital Solutions BDC Corp. reported that non-qualifying assets represented 1.7% of total net assets as of September 30, 2026, down from 3.2% at year-end 2025. The company also disclosed a significant affiliated investment in Voyatek with a fair value of approximately $23.1 million and noted that its credit facility's unused commitment fee expired in June 2026.
Spero Therapeutics reported third quarter 2026 financial results, ending the period with $107.9 million in cash and cash equivalents. The company is focused on advancing its in-licensed anti-CD40L antibody, SP001, toward a Phase 2 trial in IgG4-related disease expected to initiate in Q2 2027.
“We believe SP001 represents a compelling opportunity to address significant unmet medical needs across multiple immune-mediated diseases. With a strong financial position and the recent additions to our team that strengthen the capabilities needed to support our next stage of development, we believe we are well positioned to execute our clinical development strategy.”
Esther Rajavelu, President and Chief Executive Officer
Battalion Oil Corp reported total operating revenues of $45.6 million for the quarter ended September 30, 2026, with a net income from operations of $5.0 million. However, the company faced a significant net loss on derivative contracts of $44.8 million during the quarter, compared to a gain in the prior year period.
Starling Oncology, Inc. furnished an updated investor presentation as Exhibit 99.1 to be used in upcoming meetings with investors. This filing is an amendment (Form 8-K/A) that supersedes a previous version of the presentation filed earlier the same day.
Synchrony Card Issuance Trust Debt Financing Update with BofA Securities, Inc.
Synchrony Card Funding, LLC and Synchrony Bank entered into an underwriting agreement with BofA Securities, Barclays Capital, and Wells Fargo Securities for the issuance of Class A(2026-3) Notes. The notes will be issued by the Synchrony Card Issuance Trust under an existing master indenture and a new terms document. This filing establishes the legal and underwriting framework for the upcoming debt issuance.
Silexion Therapeutics Corp is a development-stage biotechnology company focused on its Phase 2/3 clinical trial of SIL204 for pancreatic cancer. As of November 12, 2026, the company reported 649,528 ordinary shares outstanding and continues to operate as an emerging growth company with no product revenue to date.
Aramark filed an amendment to a previous 8-K to report that director Antony F. Spring has been appointed to the Compensation and Human Resources and Finance and Technology committees of the Board. Mr. Spring was originally elected to the Board on August 4, 2026, but committee assignments had not been determined at that time.
Innovative Food Holdings reported a consolidated net income of $2.03 million for the nine months ended September 30, 2026, a significant recovery from a $2.09 million loss in the prior year period. This improvement was driven by a $1.5 million gain from discontinued operations and a $2.69 million gain on the disposition of assets, despite a decrease in total revenue from $47.3 million to $37.2 million.
DiaMedica Therapeutics reported a net loss of $31.5 million for the nine months ended September 30, 2026, driven by increased research and development expenses for its lead candidate DM199. The company's cash and marketable securities decreased to $34.9 million from $59.9 million at the end of 2025, reflecting ongoing clinical trial costs for preeclampsia and fetal growth restriction programs.
Laird Superfood reported Q3 2026 financial results, featuring a 225% revenue increase to $42.0 million following the acquisitions of Navitas Organics and Terrasoul Superfoods. The company achieved profitability with net income of $1.7 million and Adjusted EBITDA of $2.1 million, driven by acquisition synergies and retail distribution expansion.
Term
Q3 2026
“Q3 was our first full quarter operating Laird Superfood, Navitas Organics, and Terrasoul Superfoods as one platform. Net sales grew 225% to $42.0 million, and Adjusted EBITDA reached $2.1 million as we began capturing synergies. We remain excited by the consumer opportunities in front of us and are increasing our marketing activity to capture and sustain growth from the health and wellness trends that continue to play into the strenghts of our brands. Our new executive team is now in place and, with $17.3 million in cash and no debt, we are well positioned for continued, profitable growth.”
Algorhythm Holdings $2M Debt Financing with Streeterville Capital, LLC
Algorhythm Holdings, Inc. made a voluntary $2.0 million prepayment against its outstanding Secured Pre-Paid Purchase #4 (PPP #4) using restricted cash. The lender, Streeterville Capital, LLC, agreed to waive the standard 110% prepayment premium, reducing the company's total outstanding balance under its securities purchase agreement to approximately $8.14 million.
Battalion Oil Corporation reported third quarter 2026 financial results, generating sales volumes of 11,359 Boe/d and total operating revenue of $45.6 million. The company highlighted a significant balance sheet transformation, ending the quarter with $92.1 million in cash and reducing net debt to $70.4 million. Additionally, the company executed a transformative midstream transaction to shift crude transportation from trucking to pipeline, expected to significantly lower gathering costs.
Term
Q3 2026
“Our commitment to operational excellence has shown in our third quarter results. I’m proud of the team and look forward to continued execution”
Cytokinetics Insider B. Lynne Parshall Sells $274K of Stock
B. Lynne Parshall sold 5,000 shares of Cytokinetics Inc at $54.17 to $55.26 a share (average $54.73) in 2 transactions, worth $274K in total on Nov 9, 2026. Shares held after the trade: 5,784 (-30.6%).
Everpure Chief Visionary Officer John Colgrove Sells $10.1M of Stock
John Colgrove, Chief Visionary Officer, sold 99,993 shares of Everpure, Inc. at $98.88 to $104.75 a share (average $100.77) in 13 transactions, worth $10.1M in total on Nov 10, 2026. Shares held after the trade: 2,365,007 (-0.1%).
Immunovant Insider Atul Pande Sells $108K of Stock
Atul Pande sold 3,000 shares of Immunovant, Inc. at $36.00 a share, worth $108K in total on Nov 11, 2026. Shares held after the trade: 116,731 (-2.5%).
American Battery Materials Inc. reported a net loss of $6.09 million for the nine months ended September 30, 2026, driven by significant non-cash expenses related to debt extinguishment and note modifications. The company faces substantial liquidity challenges with a working capital deficit of $13.3 million and only $1,465 in cash, leading to an expressed doubt about its ability to continue as a going concern.
Mountain Crest Acquisition Corp. V M&A Deal with CubeBio Co., Ltd.
Shareholders of Mountain Crest Acquisition Corp. V approved the definitive business combination agreement with South Korea-based CubeBio Co., Ltd. The transaction will result in both companies becoming subsidiaries of a new entity, VIANIQ Holdings Limited (formerly CubeBio Holdings Limited). The approval marks a major step toward completing the merger and taking the combined entity public.
Tutor Perini Insider Dale Anne Reiss Sells $831K of Stock
Dale Anne Reiss sold 8,881 shares of Tutor Perini Corp at $93.00 to $94.09 a share (average $93.57) in 2 transactions, worth $831K in total on Nov 9, 2026. Shares held after the trade: 26,982 (-13.5%).
Rallybio Corp announced that its pending merger with Avenzo Therapeutics is expected to close following the close of trading on November 20, 2026. The company also provided a timeline update for its previously announced special cash distribution of $13.90 per share, which will be paid to stockholders of record as of November 5, 2026, following Nasdaq due bill procedures.
For the nine months ended September 30, 2026, Talphera reported a net loss of $10.9 million, compared to a $10.5 million loss in the prior year period. Operating expenses increased to $12.0 million, driven by higher research and development costs related to the Niyad product candidate, while cash and short-term investments totaled $14.2 million.
Everpure CEO Charles H. Giancarlo Sells $7.05M of Stock
Charles H. Giancarlo, CEO, sold 70,000 shares of Everpure, Inc. at $98.93 to $104.64 a share (average $100.77) in 7 transactions, worth $7.05M in total on Nov 10, 2026. Shares held after the trade: 1,369,735 (-0.0%).
DiaMedica Therapeutics reported Q3 2026 financial results and provided clinical updates on its DM199 programs. The company completed enrollment in the first two cohorts of its Phase 2 fetal growth restriction (FGR) trial and surpassed the 200-participant enrollment threshold for its ReMEDy2 Phase 2/3 acute ischemic stroke trial, with an interim analysis expected in Q1 2027.
Term
Q3 2026
“During the third quarter and recent weeks, we continued to advance DM199 across each of our clinical programs, including completing enrollment in the first two cohorts of our Phase 2 early-onset fetal growth restriction study and reaching the 200-participant enrollment threshold for the planned interim analysis of ReMEDy2.”
Rick Pauls, President and Chief Executive Officer
“Our clinical programs are providing important opportunities to evaluate the pharmacologic effects of DM199 across pregnancy-related vascular disorders and acute ischemic stroke.”
Mountain Crest Acquisition Corp. V Other 8-K Filing
Mountain Crest Acquisition Corp. V stockholders approved an amendment to the company's charter to extend the deadline for completing an initial business combination to May 16, 2027. In connection with the vote, stockholders redeemed 64,297 shares of common stock.
Ecolab Insider David MacLennan Buys $185K of Stock
David MacLennan bought 600 shares of Ecolab Inc. at $308.12 a share, worth $185K in total on Nov 12, 2026. Shares held after the trade: 26,225 (+2.3%).
Sidus Space announced that its financial statements for the fiscal years 2024 and 2025, along with several quarterly reports through mid-2026, should no longer be relied upon. The company intends to restate these affected financial statements in a comprehensive amendment to its 2025 Annual Report and its Q3 2026 Quarterly Report. This non-reliance determination was made by the Audit Committee and management due to identified accounting errors.
CapsoVision reported a net revenue of $10.0 million for the nine months ended September 30, 2026, a slight increase from $9.6 million in the prior year. However, the company experienced a net loss of $21.9 million during this period, driven by high research and development expenses as they pursue FDA clearances for new products like the CapsoCam Colon capsule and AI capabilities.